Impact of Remission Induction Chemotherapy Prior to Allogeneic SCT in Relapsed and Poor-response Patients With AML
Status:
Recruiting
Trial end date:
2023-05-01
Target enrollment:
Participant gender:
Summary
This trial compares outcome of two treatment strategies for patients with high-risk AML who
failed to achieve or maintain a complete remission with standard therapy. Patients will be
randomized between two strategies. The standard strategy is aimed at achieving a complete
remission by aggressive salvage chemotherapy using high dose cytarabine and mitoxantrone, .
The alternative is a less toxic disease-control strategy of disease monitoring and, if
necessary, low-dose cytarabine or mitoxantrone prior to allogeneic transplantation, which
should be performed as soon as possible.